IL18 and lung carcinoma: Plasma cytokines IL-18 and CXCL10 could indicate the anti-PD-1/PD-L1 treatment response in lung cancer patients and play an important role in selecting patients benefiting from PD-1/PD-L1 inhibitors [26].